Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Marilena, Granzotto"'
Autor:
Stefania Braidotti, Marilena Granzotto, Debora Curci, Barbara Faganel Kotnik, Natalia Maximova
Publikováno v:
Biomedicines, Vol 12, Iss 8, p 1853 (2024)
Optimized use of prophylactic or therapeutic donor lymphocyte infusions (DLI) is aimed at improving clinical outcomes in patients with malignant and non-malignant hematological diseases who have undergone allogeneic hematopoietic stem cell transplant
Externí odkaz:
https://doaj.org/article/e724ab7d952543bc85fe38b663375f3e
Autor:
Sara Mohamed, Elisa Lucchini, Francesca Sirianni, Marika Porrazzo, Laura Ballotta, Mario Ballerini, Giovanni Maria De Sabbata, Eleonora De Bellis, Ilaria Cappuccio, Marilena Granzotto, Barbara Toffoletto, Ilaria Fortunati, Anna Russignan, Emilia Elzbieta Florea, Lucio Torelli, Francesco Zaja
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
messenger RNA (mRNA)-Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccines such as BNT162b2 became available in late 2020, but hematological malignancy patients (HM pts) were not evaluated in initial registration trials. We hereby repo
Externí odkaz:
https://doaj.org/article/4745d20e03614202b13ffcceaf23b8c2
Autor:
Stefania Braidotti, Raffaella Franca, Marilena Granzotto, Elisa Piscianz, Alberto Tommasini, Marco Rabusin, Gabriele Stocco, Giuliana Decorti
Publikováno v:
Frontiers in Bioscience-Landmark, Vol 27, Iss 2, p 039 (2022)
Background: The T-cell engager antibody blinatumomab (BlincytoTM) represents a promising rescue therapy for relapsed/refractory CD19+ acute lymphoblastic leukemia (B-ALL), although ~20–30% of patients still do not respond to treatment. Blinatumo
Externí odkaz:
https://doaj.org/article/36966ce399ad48d1b3f92178fee1506e
Autor:
Giuliana Decorti, Gabriele Stocco, Marco Rabusin, Alberto Tommasini, Elisa Piscianz, Marilena Granzotto, Raffaella Franca, Stefania Braidotti
Background: The T-cell engager antibody blinatumomab (BlincytoTM) represents a promising rescue therapy for relapsed/refractory CD19+ acute lymphoblastic leukemia (B-ALL), although ∼20-30% of patients still do not respond to treatment. Blinatumomab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c15dd96acace8c0958d00c964de68403
https://www.imrpress.com/journal/FBL/27/2/10.31083/j.fbl2702039
https://www.imrpress.com/journal/FBL/27/2/10.31083/j.fbl2702039
Autor:
Stefania, Braidotti, Raffaella, Franca, Marilena, Granzotto, Elisa, Piscianz, Alberto, Tommasini, Marco, Rabusin, Gabriele, Stocco, Giuliana, Decorti
Publikováno v:
Frontiers in bioscience (Landmark edition). 27(2)
The T-cell engager antibody blinatumomab (BlincytoTM) represents a promising rescue therapy for relapsed/refractory CD19+ acute lymphoblastic leukemia (B-ALL), although ~20-30% of patients still do not respond to treatment. Blinatumomab creates a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a09bfdd0a67295b12f295c08d133b4b0
https://pubmed.ncbi.nlm.nih.gov/35226982
https://pubmed.ncbi.nlm.nih.gov/35226982
Autor:
Nelly Mezzaroba, Sonia Zorzet, Erika Secco, Stefania Biffi, Claudio Tripodo, Marco Calvaruso, Ramiro Mendoza-Maldonado, Sara Capolla, Marilena Granzotto, Ruben Spretz, Gustavo Larsen, Sandra Noriega, Marianna Lucafò, Eduardo Mansilla, Chiara Garrovo, Gustavo H. Marín, Gabriele Baj, Valter Gattei, Gabriele Pozzato, Luis Núñez, Paolo Macor
Publikováno v:
PLoS ONE, Vol 8, Iss 11 (2013)
Externí odkaz:
https://doaj.org/article/be57c3f9391e4037b69315689724f5ac
Autor:
Nelly Mezzaroba, Sonia Zorzet, Erika Secco, Stefania Biffi, Claudio Tripodo, Marco Calvaruso, Ramiro Mendoza-Maldonado, Sara Capolla, Marilena Granzotto, Ruben Spretz, Gustavo Larsen, Sandra Noriega, Marianna Lucafò, Eduardo Mansilla, Chiara Garrovo, Gustavo H Marín, Gabriele Baj, Valter Gattei, Gabriele Pozzato, Luis Núñez, Paolo Macor
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e74216 (2013)
Current B-cell disorder treatments take advantage of dose-intensive chemotherapy regimens and immunotherapy via use of monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents, and often cause adver
Externí odkaz:
https://doaj.org/article/e8db882aa0d141d3af360ac7dbd26da8
Autor:
Francesca Barbieri, Roberto Simeone, Annalisa Marcuzzi, Davide Zanon, Lorenzo Monasta, Alberto Tommasini, Roberto Sala, Natalia Maximova, Marilena Granzotto
Publikováno v:
Cancer Medicine
Myeloablative conditioning is a well‐established procedure that precedes hematopoietic stem cell transplantation (HSCT), particularly in pediatric patients. In the period directly following transplantation, several factors may contribute to complic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bdd08504e25ba0a260eba78a6fc8d4a
https://hdl.handle.net/11368/2943288
https://hdl.handle.net/11368/2943288
Autor:
Sandra, Perticarari ∗, Gianni, Presani, Mario, Prodan, Marilena, Granzotto, Rossella, Murgia, Marina, Cinco
Publikováno v:
In Microbial Pathogenesis 2003 35(4):139-145
Autor:
Antonio Giacomo Grasso, Marilena Granzotto, Natalia Maximova, Davide Zanon, Alessandra Maestro, Stefano Loiacono
Publikováno v:
Cancers
Cancers, Vol 10, Iss 9, p 291 (2018)
Cancers, Vol 10, Iss 9, p 291 (2018)
Acute myeloid leukemia with myelodysplastic changes and monosomy 7 is a rare form of pediatric leukemia associated with very poor disease-free survival. The refractoriness of the disease is due to the protection offered by the bone marrow niche, maki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88a09ed214a7773d9405fd19ccdb67a9
http://europepmc.org/articles/PMC6162695
http://europepmc.org/articles/PMC6162695